�������t¶��

Jeong said even though the risk of serious side effects in bioequivalence studies is minimal, they made up an exploitative industry not unlike the now-outlawed practice of selling blood that was once a source of income for the poor.

Many of them are for bioequivalence studies that test copies of off-patent drugs already on the market.

In one called “Bioequivalence Romance,” an aspiring cop who has failed the police exam eight times undergoes a drug study and turns brilliant overnight — but later develops side effects.

Regulators had earlier restricted the use of commercial review boards to oversee only bioequivalence studies, which explore whether a patented drug and its generic version work in the same way.

“Celgene has sold and will sell our groundbreaking products to generic manufacturers for the purposes of bioequivalence testing, subject to reasonable safety-related and business requirements. Generic versions of Thalomid and Revlimid are licensed to enter the market in coming years.”